Home » Market Wire » Lion Biotechnologies Manufacturing Capabilities and Research Programs Unaffected by Review of National Cancer Institute’s Manufacturing Facilities

Lion Biotechnologies Manufacturing Capabilities and Research Programs Unaffected by Review of National Cancer Institute’s Manufacturing Facilities

Sunday, April 17, 2016, 10:00
Market Wire
Add a comment

Lion’s Phase 2 study of lead product, LN-144, for the treatment of refractory, metastatic melanoma continues uninterrupted

Source: http://www.marketwired.com/mw/release.do?id=2115520&sourceType=3

Share
Delicious Digg Design Float Mixx Reddit StumbleUpon Technorati

About the Author

admin has written 21640 stories on this site.

« Time And Technology Expert Karla Brandau To Speak At Produce Marketing Association’s Conference

‘The Jungle Book’ Unleashes A Mighty 3D Roar At The Box Office With Approximately 43% Of The Estimated $103.6 Million Domestic Gross Opening Weekend »

Lion Biotechnologies Manufacturing Capabilities and Research Programs Unaffected by Review of National Cancer Institute’s Manufacturing Facilities

About the Author

Subscribe

Archives